Paradoxical Reactions to Anti-TNFa and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

0571652 - MBÚ 2024 RIV NZ eng J - Článek v odborném periodiku
Jirásková Zákostelská, Zuzana - Reiss, Zuzana - Tlaskalová-Hogenová, Helena - Rob, F.
Paradoxical Reactions to Anti-TNFa and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?
Dermatology and Therapy. Roč. 13, č. 4 (2023), s. 911-933. ISSN 2193-8210. E-ISSN 2190-9172
Grant CEP: GA MZd(CZ) NV18-09-00493; GA MZd(CZ) NU22J-05-00056; GA MZd(CZ) NU22-01-00077
Institucionální podpora: RVO:61388971
Klíčová slova: Skin microbiota * Gut microbiota * Psoriasis * ibd * TNF alpha * il-17 * Biologics * Skin adverse events * Gut-skin axis
Obor OECD: Immunology
Impakt faktor: 3.4, rok: 2022
Způsob publikování: Open access
https://link.springer.com/article/10.1007/s13555-023-00904-4

Psoriasis is a chronic, immune-mediated, inflammatory disease primarily affecting the skin. It is currently coming to light that patients with psoriasis have disrupted intestinal barrier and often suffer from comorbidities associated with the gastrointestinal tract. Moreover, there is growing evidence of both cutaneous and intestinal paradoxical reactions during biologic treatment in patients with psoriasis. This review focuses on barrier defects and changes in immune responses in patients with psoriasis, which play an important role in the development of the disease but are also influenced by modern biological treatments targeting IL-17 and TNF alpha cytokines. Here, we highlight the relationship between the gut-skin axis, microbiota, psoriasis treatment, and the incidence of paradoxical reactions, such as inflammatory bowel disease in patients with psoriasis. A better understanding of the interconnection of these mechanisms could lead to a more personalized therapy and lower the incidence of treatment side effects, thereby improving the quality of life of the affected patients.
Trvalý link: https://hdl.handle.net/11104/0342919